Top Story

Mismatch repair deficiency predicts response to pembrolizumab in several cancer types

May 29, 2015

Read the Perspective from Lynn M. Schuchter, MD, FASCO

CHICAGO — Mismatch repair deficiency may be the first genomic marker to predict how patients with cancer will respond to immune checkpoint blockade with the anti–PD-1 antibody pembrolizumab, according to phase 2 study results presented at the ASCO Annual Meeting.

An analysis that included patients with several cancer types showed those with mismatch repair (MMR)-deficient tumors demonstrated a dramatically higher response rate and significantly longer PFS after treatment with pembrolizumab (Keytruda, Merck) than those who did not have the abnormality, characterized as MMR proficient.

In the Journals

Serial biomarker levels may better detect epithelial ovarian cancer

May 28, 2015
Monitoring changes in annual serum cancer antigen 125 levels could detect twice the number of women with invasive epithelial ovarian cancer compared with standard…
Arul M. Chinnaiyan, MD, PhD Cover StoryPublication Exclusive

Despite promise, ‘maximum potential’ of precision medicine yet to be reached

HemOnc Today, May 25, 2015
Precision medicine has garnered tremendous public attention since President Barack Obama established it as a national priority during his State of the Union address.The…
Robert L. Coleman, MD Association News

Society of Gynecologic Oncology president begins 1-year term

May 16, 2015
Robert L. Coleman, MD, recently began his 1-year term as president of the Society of Gynecologic Oncology and the Foundation for Gynecologic Oncology.
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
4131332248001 th

Antibody-drug conjugate shows promise for NSCLC, ovarian cancer

June 12, 2014
CHICAGO — Howard A. Burris, MD, chief medical officer at the Sarah Cannon Research Institute, offers his…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News CoveragePerspective

Mismatch repair deficiency predicts response to pembrolizumab in several cancer types

May 29, 2015
CHICAGO — Mismatch repair deficiency may be the first genomic marker to predict how patients with cancer will respond to immune checkpoint…
In the Journals

Serial biomarker levels may better detect epithelial ovarian cancer

May 28, 2015
Monitoring changes in annual serum cancer antigen 125 levels could detect twice the number of women with invasive epithelial ovarian cancer compared…
Arul M. Chinnaiyan, MD, PhD Cover StoryPublication Exclusive

Despite promise, ‘maximum potential’ of precision medicine yet to be reached

HemOnc Today, May 25, 2015
Precision medicine has garnered tremendous public attention since President Barack Obama established it as a national priority during his State of…
Robert L. Coleman, MD Association News

Society of Gynecologic Oncology president begins 1-year term

May 16, 2015
Robert L. Coleman, MD, recently began his 1-year term as president of the Society of Gynecologic Oncology and the Foundation for Gynecologic…
Industry News

Society of Gynecologic Oncology outlines recommendations for ovarian cancer prevention

May 15, 2015
The Society of Gynecologic Oncology released several recommendations intended to help women reduce their risk for ovarian cancer.Advances in the…
Akila N. Viswanathan, MD, MPH In the JournalsPerspective

Bevacizumab combination safe, effective for endometrial cancer

May 13, 2015
The addition of postoperative bevacizumab to chemotherapy and pelvic intensity-modulated radiotherapy induced high survival rates in patients with…

What are ovarian cancer symptoms?

May 12, 2015
Ovarian cancer is a type of cancer that develops in the ovaries, which produce a woman’s eggs and reproductive hormones. Although ovarian…

How does obesity influence cancer risk?

May 7, 2015
An estimated 4% of cancers in men and 7% of cancers in women are associated with obesity, according to the NCI.People who are obese are at increased…
Meeting News Coverage

Novel olaparib combination shows activity in ovarian, breast cancers

May 1, 2015
PHILADELPHIA — A combination treatment composed of the PARP inhibitor olaparib and the investigational PI3K inhibitor BKM120 demonstrated…
In the Journals

Quadrivalent HPV vaccine provides early benefit in adolescent girls

May 1, 2015
Girls aged between 14 and 17 years experienced early beneficial effects with the quadrivalent HPV vaccine; therefore, offering additional…
More Headlines »
morganatic-roan